首页|Emerging therapeutics in the management of connective tissue disease. Part I. Lupus erythematosus and Sj?gren syndrome

Emerging therapeutics in the management of connective tissue disease. Part I. Lupus erythematosus and Sj?gren syndrome

扫码查看
原文链接
  • NSTL
  • Elsevier
? 2022 American Academy of Dermatology, Inc.The management of connective tissue diseases is dramatically evolving with the advent of biologics and novel oral systemic therapeutics. Despite involvement in the care of these complex patients, there is a knowledge gap in the field of dermatology regarding these emerging agents. The first article in this continuing medical education series discusses new and emerging therapeutics for lupus erythematosus and Sj?gren syndrome that target cells, intracellular signaling pathways, and cytokines.

clinical trialscurrent managementcutaneous lupus erythematosusnew treatmentsSj?grensystemic lupus erythematosus

Skudalski L.、Shahriari N.、Torre K.、Santiago S.、Bibb L.、Kodomudi V.、Grant-Kels J.M.、Lu J.

展开 >

Geisinger Commonwealth School of Medicine

Department of Dermatology Brigham and Women's Hospital Harvard Medical School

Department of Dermatology University of Connecticut Health Center

2022

10.1016/j.jaad.2021.12.067

Journal of the American Academy of Dermatology

Journal of the American Academy of Dermatology

ISTP
ISSN：0190-9622
年,卷(期)：2022.87(1)
  • 1
  • 121